Ajax Therapeutics Inc. has divulged tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of hematologic cancer (particularly, leukemia and lymphoma), myelofibrosis, polycythemia vera and essential thrombocythemia.